Many people with pre-cancerous blood disorders have low vitamin C. A new randomized, double-blind phase 2 trial (109 patients) tested 1,000 mg of oral vitamin C daily for a year.
Levels normalized, adverse events were fewer, and an exploratory analysis showed higher survival at about 3 years. But abnormal cell growth did not differ significantly, and a larger phase 3 trial is needed. Promising, not proven. #VitaminC #CancerResearch #Hematology
https://scentsofscience.com/2026/10/20/vitamin-c-pre-cancerous-blood-disorders-phase-2-trial/
